Nasdaq · Healthcare
AbCellera Biologics Inc. (ABCL)
As-reported financials and recent SEC filings for AbCellera Biologics Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$75.1M
Net income
$-146.4M
Net margin
—
Diluted EPS
$-0.49
ROE
-15.1%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M |
| Gross profit | — | — | — | — | — |
| Operating income | $-217.1M | $-314.8M | $-237.2M | $216.5M | $204.4M |
| Net income | $-146.4M | $-162.9M | $-146.4M | $158.5M | $153.5M |
| Diluted EPS | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-06
View on EDGAR →42026-07-06
View on EDGAR →32026-07-06
View on EDGAR →42026-07-06
View on EDGAR →8-K2026-06-17
View on EDGAR →42026-06-12
View on EDGAR →8-K2026-06-12
View on EDGAR →42026-06-12
View on EDGAR →Largest Healthcare peers
Go deeper on ABCL
Search AbCellera Biologics Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.